Toronto, Ontario--(Newsfile Corp. - January 27, 2022) - PurMinds NeuroPharma, a Canadian neuroscience company pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases, will be presenting at Psychedelic Capital: Jan 2022 by Microdose on Thursday, January 27.
Get Free Tickets Here: https://microdose.buzz/PURMINDS
The coupon code PURMINDS will also work upon checkout.
Date & Time of the Event: 01/27/2022 01:30pm EST
Date & Time of Their Panel: 01/27/2022 03:15pm EST
While the presentation is live streamed, lifetime access to recordings will be available to all ticket holders.
What is Psychedelic Capital: Jan 2022?
Psychedelic Capital covers the top companies, latest IPOs, newest opportunities & deepest insights in the psychedelic industry.
For more information, please visit: https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-jan-2022/
About PurMinds NeuroPharma
PurMinds NeuroPharma is pursuing breakthrough solutions for devastating neurological disorders with a special emphasis on neurodegenerative diseases. We strive to deliver the right drugs to the right patients by utilizing technology and championing next generation drug development approaches.
The key to discovering and developing better drugs is to understand the disease mechanism. The more we understand, the more effective our therapeutics will be at delivering the right drug to the right patient.
PurMinds' PurPrecision neuromedicine development platform will be used to analyze iPSC-derived neurons from diseased patients and non-neurological healthy controls using multi-omics and integrative computational analyses.
PurMinds champions psychoactive pharmaceutical investigation and believes in the power of psychedelics as a useful tool and catalyst for next generation CNS drug development.
Contact
For any inquiries related to PurMinds NeuroPharma and any of their programs, you can visit their website at https://www.purminds.com/ or send an e-mail to info@purminds.com.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111794
